XNAS · Healthcare · Diagnostics & Research
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-28 | Q1 2026 | 0.08 | 0.34 | +325.00% | $117.7M | ✅ Beat | -11.41% | -5.52% | +3.61% |
| 2026-02-24 | Q4 2025 | 0.23 | 0.12 | -47.83% | $108.4M | ❌ Miss | +3.90% | -2.34% | -9.25% |
| 2025-11-04 |
| Q3 2025 |
| 0.04 |
| 0.28 |
| +600.00% |
| $100.1M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-06 | Q2 2025 | 0.03 | 0.10 | +233.33% | $86.7M | ✅ Beat | -7.18% | -7.40% | +5.50% |
| 2025-04-30 | Q1 2025 | 0.07 | 0.09 | +28.57% | $84.7M | ✅ Beat | -10.72% | -12.50% | +0.65% |
| 2025-02-26 | Q4 2024 | 0.15 | 0.18 | +20.00% | $86.6M | ✅ Beat | -0.19% | -3.22% | -14.88% |
| 2024-11-04 | Q3 2024 | 0.01 | 0.14 | +1300.00% | $82.9M | ✅ Beat | -0.13% | +1.79% | +13.04% |
| 2024-07-31 | Q2 2024 | -0.14 | 0.25 | +278.57% | $92.3M | ✅ Beat | +17.96% | +21.46% | +53.73% |
Showing last 8 quarters.